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Abstract
Aims: The purpose of this study was to assess the impact of oral mucositis (OM) on oral-health related quality of life (QoL) among
pediatric patients with cancer using Patient-Reported Oral Mucositis Symptom (PROMS) questionnaire. Methods: Seventy-five
consequtive newly diagnosed patients undergoing chemotherapy because of different forms of cancer between the age of 8 and 18
yrs were included in the study. Children undergoing chemotherapy were required to complete the questionnaire at admission and
weekly during the treatment. Results: Oral mucositis due to therapy was observed in 53/75 patients. The total PROMS score has
increased gradually with a peak on day 21. A transient decrease of the total PROMS score was marked on day 28 followed by a
second peak on day 35. We found significant correlations between WBC and the frequency of oral mucositis on day 7, 14 and 21.
We found significant association between PROMS scores and oral mucositis scores according to the WHO protocol. Conclusions:
According to our findings, oral mucositis is a common side-effect of chemotherapy which develops often in children with cancer.
Based on its easy administration, PROMS questionnaire is suitable to measure self-reported changes in oral health of pediatric
cancer patients.
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Introduction
Oral mucositis (OM) is a painful and debilitating complication
of cancer chemotherapy. The condition among pediatric
patients is more frequent and severe compared to adults,
especially in children with leukaemia [1-3]. OM is
characterized by painful inflammation, ulceration and
erythema of the oral mucosa; however, mucositis can occur
anywhere along the gastrointestinal tract [4]. In mucositis,
natural rate of mucosal cell death is accelerated by anticancer
drugs. The degree of pain is usually related to the extension of
tissue damage. Patients with OM may experience trouble in
eating, drinking, swallowing or even speaking. OM has been
shown to be associated with other adverse events caused by
chemotherapy, such as loss of body weight, dehydration and
fever. Moreover, OM has an adverse impact on clinical
outcome of the malignant condition and on oral-health related
quality of life (OHRQoL) [1]. Therefore, it is important to
assess accurately OM-related symptoms of patients in order to
prevent and to properly treat this side-effect. A number of
clinician-rated scoring systems to detect and quantitate OM
have been developed; however, there is no universally
accepted self-administered OM assessment scale.
Aim
The purpose of this study was to evaluate the administration
of a Patient-Reported Oral Mucositis Symptom (PROMS)
scale among pediatric cancer patients, to compare PROMS-
derived data with oral health measures rated by a dental
clinician and to establish the adverse impact of OM on
OHRQoL in children with cancer.
Methods
Patients and study design
Seventy-five consequtive newly diagnosed patients
undergoing chemotherapy because of different forms of
childhood cancer (29 boys and 46 girls) between the age of 8
yrs and 18 yrs (mean: 12 ± 4.3 yrs) were enrolled in the study
between Jan 2, 2011 and Dec 31, 2012. The male/female ratio
was 0.41. Fourty-five (60%) patients (12 boys and 33 girls,
mean (±SD) age: 10 (±2.5) years) suffered from acute
lymphoblastic leukemia (ALL), which is the most common
type of childhood cancer. Patients with ALL were subjected to
subgroup analysis in addition to the evaluation of the total
patient population. Neither the age (mean ± SD = 10 ± 2.5
yrs), nor the male: female ratio 0.36 of ALL patients differed
significantly from the total study population. Diagnosis and
cancer treatment was performed at the Department of
Pediatrics, University of Debrecen, according to the
guidelines of the Hungarian Pediatric Oncology-Hematology
Group. Diagnosis and treatment schedule of patients in course
of antineoplastic chemotherapy are given in Table 1.
Inclusion criteria involved the patient’s ability to complete
the PROMS questionnaire without assistance and signing of
the informed consent by the legal caregiver and by the patient.
Exclusion criteria were the following: age < 8 and > 18 years;
noncompliance with completing of the questionnaires at the
scheduled sampling times (see below); patient’s incapability
to complete the PROMS questionnaire without assistance;
patients not surviving the observation period. Informed
consent was taken on first admission by a trained dental
examiner (Á.J.). Before signing of the informed consent,
patients and their legal caregivers were informed about the
nature of the study in order to decide whether or not they
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wished to participate in the study. Altogether, 11 patients were
excluded from the study.
Table 1. Diagnosis and treatment schedule of patients in course of antineoplastic chemotherapy.
Patients' characteristics   
Sex
Male N=29
Female N=46
Mean age ± SD (range) (years) 12 ± 4.3 yrs
Diagnosis Cytostatic drugs applied  
1. Acute lymphoblastic leukaemia
Vincristine, Prednisolon, Daunorubicin, L-
Asparaginase (ALL-IC BFM 2002 protocol induction
phase) [20]
N=45
2. Acute myeloid leukaemia Daunorubicin, Cytosine arabinoside, Etoposide(AML-BFM 98 protocol) [21] N=5
3. Hodgkin lymphoma Doxorubicin, Prednisolon, Vincristine, Etoposide(EuroNet-PHL study) [22] N=6
4. Non-Hodgkin lymphoma
Cyclophosphamide, Adriamycin, Vincristine,
Prednisolon (NHL-BFM 95 protocol induction
phase) [23]
N=4
5. Hepatoblastoma Cisplatin, Doxorubicin (PLADO) [24] N=3
6. Wilms tumor Dactinomycin, Vincristine, Epirubicin (SIOP WT01)[25.] N=3
7. Rhabdomyosarcoma Vincristine (CW-high Risk branch) [26] N=2
8. Serous epithelial ovarian cancer Docetaxel, Carboplatin, [27] N=2
9. medulloblastoma Lomustine, Vincristine, Cisplatin (VEP) [28] N=2
10. Ewing sarcoma VIDE block: Vincristine, Cyclophosphamide,Doxorubicin, Etoposide (Euro-Ewing99) [29] N=1
11. Nasopharyngeal carcinoma Cisplatin, 5-Fluorouracil, Docetaxel + radiationtherapy (total doses of 60 Gy) [30] N=1
12. Retinoblastoma Carboplatin, Vincristine, Etoposide [30] N=1
The study period started on the first admission of the
patients, i.e. prior to administering cancer treatment and the
observation period lasted up to day 35 of cancer treatment. We
established an observation period of 35 days, since induction
phase of chemotherapy of patients with ALL, representing the
largest subgroup of patients, took 33 days and 35 days
covered the first chemotherapy treatment block and the
recovery after the first treatment block in patients with other
forms of cancer.
Questionnaire
The instrument of the present investigation was the original
PROMS self-administered scale translated to Hungarian
language by the investigators [5]. The questionnaire
comprised 10 items related to most frequently occurring
complaints due to chemotherapy-induced OM, i.e. (1) mouth
pain, (2) difficulty of speaking because of mouth sores, (3)
restriction of speech because of mouth sores, (4) difficulty of
eating hard foods because of mouth sores, (5) difficulty of
eating soft foods because of mouth sores, (6) restriction of
eating because of mouth sores, (7) difficulty drinking because
of mouth sores, (8) restriction of drinking because of mouth
sores, (9) difficulty of swallowing because of mouth sores,
and (10) change in taste. Participants were required to fill in
the questionnaire according to the severity on a 100 mm long
visual analogue scale (VAS). The maximum score was 100 for
each item as well as for the total score. The higher the item
scores were the more pronounced symptoms the patients
experienced. The sum of the item scores characterized the
respondents’ oral mucosal health with higher scores
representing more impaired OHRQoL. According to PROMS
scale patients reaching at least 25 score (the maximum score
is 100) in case of at least in four items were judged as patients
affected by oral mucositis.
Patients were required to complete the questionnaire on
first admission and weekly (day 7, 14, 21, 28 and 35) during
the course of cancer treatment. Two trained dental surgeons
(Á.J., I.J.M.) performed the investigations of patients,
administered the PROMS questionnaire and registered oral
mucositis scores according to the WHO protocol, collected
and analyzed the data. Training was repeated as necessary.
Oral examinations
Mucositis was evaluated using the WHO scoring system [6].
WHO distinguishes four grades of oral mucositis according to
severity: 0- no symptoms; 1- erythema, soreness; 2- erythema,
ulceration, patient can swallow solid food; 3- erythema,
ulceration, patient cannot swallow solid food; 4- ulceration,
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pseudomembrane formation, alimentation is not possible [6].
Using ordinal grades of 0, 1, 2, 3 and 4 for the size of
erythematous areas, the size of ulceration and the grade of
restriction in swallowing patients categorized into grade 1, 2,
3 and 4 were assessed as patients affected by oral mucositis.
Periodontal condition of the participants was documented.
Dental surgeons participating in this study were trained in the
CPI system using calibrated WHO periodontal probe. With
the CPI system a score of 0 indicated healthy periodontium; a
score of 1 indicated probing up to the lowest edge of the black
band, i.e. up to 3.5 mm and bleeding; a score of 2 is the same
as a score of 1 except that calculus was found; a score of 3
was given when the black band partially disappeared,
indicating probing up to 5.5 mm, and a score of 4 was
complete disappearance of the band with probing 5.5 mm and
above [7]. In case of patients who were unable to accept
probing due to pain or limited opening during the severe
mucositis the oral examination was repeated after healing.
White blood cell count (WBC) of patients was determined
according to standard laboratory method and registered at
times of the dental examinations.
Statistical methods
The mean (±SD) values of the PROMS items were calculated
on first admission (baseline) and on day 7, 14, 21, 28 and 35
during the course of treatment. Using nonparametric rank
correlation coefficients, we estimated the correlation between
item scores and the WBC. Association between self-reported
PROMS scores and clinician-rated OM scores and its
components was established by one-way ANOVA test.
Correlations between patients’ CPI index and PROMS score
components was estimated by Spearman’s rho correlation.
The distribution of PROMS item scores and total scores at
baseline and at later time-points was represented by
histograms. Statistically significant differences from the
baseline were considered if p< 0.05.
The study was conducted in full accordance with ethical
principles of the World Medical Association Declaration of
Helsinki and approved by the institutional Review Board
(3368-2011 DEOECRKEB/IKEB). All patients and their
caregivers signed a written informed consent form.
Figure 1. a: OM in the middle third of the buccal mucosa; b: OM on the ventral surface of the tongue; c: OM in the posterior third of the
buccal mucosa.
Results
The PROMS scale was applied for a study group of 75
pediatric patients on first admission (baseline). The response
rate was: 74/75 patients (98.7%) on day 7, 64/75 patients
(85.3%) on day 14, 50/75 patients (66.7%) on day 21,
22/75patients (29.3%) on day 28 and 8/75patients (10.7%) on
day 35.
Chemotherapy-induced OM was observed in 53/75 (70.7%)
patients during the observation period according to the
PROMS scores and in 58/75 patients (77.3%) according to the
WHO OM tool evaluated by a dental surgeon. Representative
lesions are shown in Figures 1a, b, c. The total PROMS score
has increased significantly and gradually with a peak on day
21 of therapy (mean on first admission: 6.18; mean on day 7:
23.30; mean on day 14: 30.97; mean on day 21: 39.28).
Figure 2. Changes in total PROMS score of the total study
population and patients with ALL throughout the study
observation period.
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A significant transient decrease of the total PROMS score
was marked on day 28 (mean: 29.47) followed by a significant
second peak on day 35 (mean: 38.73) (Figure 2). With the
exception of “change in taste” PROMS item scores showed
the same significant increase up to day 21, followed by a
transient decrease on day 28 and a second peak on day 35.
“Change in taste” item scores increased significantly and
constantly until day 35. “Difficulty of eating hard foods” was
characterized by the highest (mean: 52.90) scores on day 21,
the most critical period of chemotherapy (Figure 3). In
contrast, the total PROMS scores and item scores of patients
with ALL had a significant single peak on day 21 (mean:
42.92) which was followed by a constant decrease until day
35 of therapy (Figure 2). All ALL patients were found in
complete clinical and hematological remission at day 33 of
treatment. Evaluating the mean item scores of the ALL
subgroup, items No 3, 4, 9 and 10 (“restriction of speech
because of mouth sores, difficulty eating hard foods, difficulty
swallowing because of mouth sores”) peaked significantly on
day 21, whereas item No 10 (“change in taste”) peaked on day
28 followed by a decrease until day 35. The remaining item
scores (No 1, 2, 5, 6, 7 and 8) of patients with ALL showed a
similar pattern to the total study group (Figure 4). Patients
with various forms of cancer other than ALL (N=30)
exhibited a similar pattern as the total study group with
respect to total PROMS score (data not shown).
Figure 3. Changes in PROMS item score values of the total study population throughout the study observation period (N=75).
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Figure 4. Changes in PROMS item score values of patients with ALL throughout the study observation period (N=45).
We found significant associations between PROMS item
scores (representing patients’ subjective assessment of OM)
and the WHO OM score and its components (representing the
objective assessment of OM) using one-way ANOVA test
(Table 2). The grade of erythema, plaque accumulation on the
oral mucosa, ulceration and alimentation difficulties evaluated
by a dental surgeon correlated significantly and meaningfully
with the total PROMS score and item scores during
hospitalization.
Table 2. Associations between WHO OM score components and PROMS score components. Probability (p values) of correlations estimated by
one-way ANOVA test. p< 0.05 were considered significant (bold boxes).
PROMS score componentsWHO OM score components Day 7 Day 14 Day 21 Day 28 Day 35
Mouth pain
erythema 0,123 <0,001 <0,001 0,003 0,008
plaque <0,001 <0,001 <0,001 0,002 0,008
ulceration nc <0,001 <0,001 0,005 nc
feeding nc <0,001 0,001 <0,001 nc
Difficulty speaking because of mouth sores
erythema 0,471 <0,001 <0,001 0,005 0,018
plaque <0,001 <0,001 <0,001 0,003 0,018
ulceration nc <0,001 <0,001 <0,001 nc
feeding nc <0,001 nc nc nc
 erythema 0,763 <0,001 <0,001 0,001 0,001
Restriction of speech because of mouth sores plaque <0,001 <0,001 <0,001 <0,001 0,001
ulceration nc <0,001 <0,001 <0,001 nc
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feeding nc <0,001 nc <0,001 nc
Difficulty eating hard foods
erythema <0,001 <0,001 <0,001 <0,001 nc
plaque nc <0,001 <0,001 <0,001 nc
ulceration nc <0,001 <0,001 0,001 nc
feeding nc nc <0,001 nc nc
Difficulty eating soft foods
erythema 0,107 <0,001 <0,001 0,001 0,001
plaque <0,001 <0,001 0,001 <0,001 0,001
ulceration nc <0,001 <0,001 0,001 nc
feeding nc <0,001 nc nc nc
 erythema 0,004 <0,001 <0,001 0,001 0,002
Restriction of eating because of mouth sores plaque <0,001 <0,001 <0,001 <0,001 0,002
ulceration nc <0,001 <0,001 <0,001 nc
feeding nc <0,001 nc nc nc
Difficulty drinking because of mouth sores
erythema 0,415 <0,001 0,003 0,001 0,014
plaque 0,058 <0,001 0,014 0,001 0,014
ulceration nc <0,001 0,002 <0,001 nc
feeding nc <0,001 nc nc nc
Restriction of drinking because of mouth sores
erythema 0,169 <0,001 0,005 0,001 0,005
plaque 0,268 <0,001 0,015 <0,001 0,005
ulceration nc <0,001 0,014 <0,001 nc
feeding nc nc nc nc nc
Difficulty swallowing because of mouth sores
erythema <0,001 <0,001 <0,001 0,007 nc
plaque nc <0,001 <0,001 0,004 nc
ulceration nc nc <0,001 0,002 nc
feeding nc <0,001 <0,001 nc nc
change in taste
erythema 0,007 <0,001 <0,001 0,033 0,009
plaque <0,001 <0,001 <0,001 0,019 0,009
ulceration nc <0,001 <0,001 0,012 nc
feeding nc nc nc <0,001 0,564
Total PROMS score
erythema 0,180 <0,001 nc 0,006 nc
plaque nc <0,001 nc nc nc
ulceration nc nc nc nc nc
feeding nc nc nc nc nc
nc= Non-conclusive: one-way ANOVA test was not successful and had no result
According to the registered pathologic pocket depths,
supra- or subgingival calculus and gingival bleeding 47/75
(63%) patients had gingivitis without clinical attachment loss
and 28/75 (37%) patients had healthy periodontium. We did
not observe severe or moderate forms of periodontitis.
Spearman’s rho correlation test did not show any significant
association between patients’ CPI index observed before
hospitalization and total PROMS score and item scores (data
not shown).
Significant correlations were found between patients’ total
PROMS score and item scores and WBC according to the
nonparametric rank correlation test (Table 3). WBC count of
the respondents correlated significantly and meaningfully with
total PROMS score on day 7, 14 and 21 (r= -0.645 on day 7;
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r= -0.585 on day 14; r=-0.709 on day 21). Correlation
coefficients (r) were considered significant if p<0.001.
Table 3. Correlation between PROMS item scores and WBC observed on days 7, 14, 21, 28 and 35 of the follow-up period.
 Day 7 Day 14 Day 21 Day 28 Day 35
mouth pain -0.522 -0.422 -0.694 -0.41 -0.862
 (<0.001) -0.009 (<0.001) -0.164 -0.006
difficulty speaking because of mouth sores -0.531 -0.528 -0.619 -0.462 -0.719
 (<0.001) -0.001 (<0.001) -0.112 -0.045
restriction of speech because of mouth sores -0.476 -0.547 -0.55 -0.593 -0.368
 (<0.001) (<0.001) -0.002 -0.033 -0.37
difficulty eating hard foods -0.503 -0.551 -0.716 -0.598 -0.886
 (<0.001) (<0.001) (<0.001) -0.031 -0.003
difficulty eating soft foods -0.423 -0.603 -0.506 -0.686 -0.59
 -0.002 (<0.001) -0.005 -0.01 -0.124
restriction of eating because of mouth sores -0.613 -0.493 -0.735 -0.601 -0.778
 (<0.001) -0.002 (<0.001) -0.03 -0.023
difficulty drinking because of mouth sores -0.494 -0.59 -0.588 -0.701 -0.473
 (<0.001) (<0.001) -0.001 -0.008 -0.237
restriction of drinking because of mouth sores -0.498 -0.566 -0.507 -0.748 -0.42
 (<0.001) (<0.001) -0.005 -0.003 -0.3
difficulty swallowing because of mouth sores -0.56 -0.37 -0.643 -0.575 -0.814
 (<0.001) -0.024 (<0.001) -0.04 -0.014
change in taste -0.555 -0.254 -0.471 -0.034 -0.886
 (<0.001) -0.129 -0.01 -0.911 -0.003
Total PROMS score -0.645 -0.585 -0.709 -0.399 -0.898
 (<0.001) (<0.001) (<0.001) -0.177 -0.002
Correlations were estimated by Spearman’s test. Rho (r) values and p values (in parentheses) were given. Taking into account the multiple hypothesis testing,
correlations were considered significant if p<0.001 for PROMS components and p<0.01 for PROMS scores (bold boxes).
Most of the mild complaints improved by using Corsodyl
(0.12% chlorhexidine digluconate containing mouth rinse).
Thirty of patients (40%) developed oral thrush throughout the
study follow-up period and required local and systemic anti-
fungal treatment.
Discussion
Early and late side-effects of childhood cancer therapy often
involve various anatomical structures of the oral cavity. Oral
mucositis is one of the most frequent and debilitating
condition [1-3,8-10]. Stomatotoxicity is due to the inhibitory
effects of cytotoxic drugs and irradiation on stem cell self-
renewal within the basal layer of the oral mucous membrane.
Bone marrow suppression may have an additive effect.
Symptoms start usually one week after of the administration
of the cytostatic agent and may last up to 2-3 weeks. Non-
keratinized surfaces, such as buccal and labial mucosa, floor
of the mouth, ventral surface of the tongue, and soft-palate are
more severely affected [11]. OM scoring systems can be
divided into two major categories: i) assessment of symptoms
may rely on measurable changes within the oral cavity
determined by a dental expert; and ii) scoring can be based on
patient-reported questionnaires. The former ones are lesser
biased by subjective complaints, the latter ones represent
OHRQoL more reliably. Among adults with head and neck
cancer receiving irradiation therapy, Etiz et al. compared and
validated five different mucositis scoring systems. Objective
mucositis scores demonstrated a strong correlation with
patient-reported symptoms [12].
Despite of the frequency of OM in children treated for
cancer, this particular side-effect has rarely been addressed by
accurate investigations. Moreover, there have been no
uniformly used scoring systems developed for the pediatric
age group to evaluate the severity of this complication;
therefore, preventive and treatment measures cannot be based
on generally accepted guidelines. Valera et al. and Soares et
al. investigated children with ALL in different phases of
antineoplastic treatment. OM was characterized by general
appearance in these studies [13,14]. Cheng et al. and Wogelius
et al. used two different self-reported scoring systems, the
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Mouth and Throat Soarness-related questions of the Oral
Mucositis Daily Questionnaire (OMDQ) and the validated
Danish version of the Child Perceptiones Questionnaire
involving a larger (No=140) and a smaller (No=18) group of
children with hematological malignancies and solid tumors,
respectively [1,15]. Jacobs et al. evaluated the reliability and
validity of the self-reported Children’s International Mucositis
Evaluation Scale (ChIMES) by comparing data with that of
two patient-reported tools, the OMDQ, and the mucositis
Visual Analogue Scale; and with two clinician-based,
objective tools, the WHO OM scoring system, and the
National Cancer Institute Common Terminology Criteria v3.0
functional/symptomatic mucositis scale. Investigating 87
children and adolescents undergoing either myeloablative
hematopoetic stem cell transplantation (HSCT) or receiving
high-dose doxorubicine (≥60 mg/m2/course) or methotrexate
(≥12 g/m2), they suggested to incorporate ChIMES into
clinical trials aimed at OM prevention and treatment in
children with cancer [16].
In this study we used the self-reported PROMS scale to
evaluate severity, onset and clinical course for the first time in
children with cancer. The measuring tool has originally been
developed in 38 adults undergoing myeloablative HSCT. In
the hands of the investigators of the Princess Margaret
Hospital, Toronto (ON, Canada), the PROMS scale had high
internal reliability and good convergent and discriminant
validity. Changes in PROMS scores strongly correlated with
changes in clinical assessment of OM [5]. Since the original
report, PROMS has been reported as useful and reliable
indicator of OM by Bezinelli et al. investigating adult HSCT
patients and by Gussard et al. investigating adults with head
and neck cancer [17,18]. In a more recent study, Gussard et al.
suggested that the association between PROMS and WHO
OM scores was nonlinear and that PROMS represented the
OM-related condition of patients more reliably than the
clinician-rated tools [19]. Table 1 can be referred for
Diagnosis and treatment schedule of patients in course of
antineoplastic chemotherapy [20-30].
Our results demonstrated that PROMS could be used
among pediatric cancer patients older than 7 years and that it
proved to be a reliable indicator of OM. There was a strong
correlation between PROMS items scores and components of
the WHO OM score, but not between PROMS scores and CPI
characterizing periodontal health. OM was a frequent finding
during the observation period, i.e. induction treatment of ALL
and first course of cytotoxic treatment applied because of
other forms of childhood cancer. More than 70% of patients
were diagnozed with OM based on the results obtained by the
PROMS questionnaire and over 77% of patients exhibited
OM according to the WHO OM tool. A mild gingivitis was
present in 63% of patients. The incidence of OM was higher
in our study than in two other pediatric studies which reported
OM incidence figures. Cheng et al. observed a 41% OM
frequency during induction or consolidation phases of
chemotherapy in children with ALL and solid tumors.
However, the observation period in that study was 14 days
and we found increasing PROMS scores up to 21 days and a
second peak in the total patient group at day 35 [1]. In the
study reported by Soares et al. the frequency of OM was 20%
among patients with ALL receiving induction treatment.
However, patients received prophylactic treatment with 0.12%
chlorhexidine gluconate solution whereas patients in our study
received only interventional management for OM [14]. Of the
pediatric studies investigating OM in children with cancer,
only Valera et al. [12] described the clinical course of oral
complications, including OM, as judged by clinical
appearance. According to their results, the frequency of oral
manifestations started to rise in the first week after the
application of cytostatic agents and lesions became more
frequent and severe for another 14-21 days when the
neutrophil leukocyte counts were low [13]. In our study
PROMS scores showed a steady increase until day 21
followed by a decrease in PROMS scores at day 28. After this
evaluation time, PROMS scores of the total study polpulation,
including children with non-ALL malignancies, exhibited a
second peak at day 35, and remained at the same level as day
28 in case of children with ALL. Similar to Valera et al. [12]
we found a strong correlation between WBC and PROMS
scores. Our results suggest, that onset and severity of OM in
children with cancer is related to the application of cytotoxic
treatment as described by others, i.e. the first patient-reported
complaints and clinical symptoms start about 7 days after the
first application of the cytotoxic agents and signs and
symptoms deteriorate during the next 2-3 weeks, as indicated
by the increasing PROMS scores in our study. Healing starts
after 4 weeks of the beginning of antineoplastic therapy.
Patients with ALL entered clinical and hematological
remission by that time and maintained their oral condition.
The majority of children with cancer different from ALL;
however, will have received their second antineoplastic
treatment block between day 21 and day 28; therefore they
experienced a second decline in oral health and, in parallel, a
second increase in PROMS scores by day 35 [5,11,17]. The
observation period limited to 35 days can be regarded as one
of the limitations of our study. However, studies investigating
treatment-related OM of cancer patients were similar or
shorter in duration with the exception of Gussard et al. who
had followed adult patients irradiated because of head and
neck cancer during the 6-7 weeks of radiotherapy and at a
single occasion 4-6 weeks after completing treatment
[1,5,16-18]. Moreover, we experienced a considerably
decreasing response rate in course of the investigation
preventing any meaningful interpretation of the results after
day 35. The significant dropout rate of our study from day 7 to
day 35 can be explained by the severe general health
condition of patients due to chemotherapy. However, in case
of patients who were unable to accept oral examination and
probing due to pain or limited opening because of severe
mucositis, oral examination was repeated after the healing, but
we lost major proportion of the questionnaires until day 35.
These challenges necessarily require multivariate, multilevel
analyses of a larger sample size. The risk of potential bias
introduced has been acknowledged. Elimination of the above
mentioned difficulties would enhance the significance of the
study.
The second limitation of our study was that the number of
patients with various forms of cancer other than ALL was too
small to allow statistically relevant analysis of the individual
subgroups. Separate prospective multi-center studies are
required to establish the exact role of PROMS questionnaire
in groups of patients with different types of childhood cancer.
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In conclusion, the present investigation represents the first
experience with the administration of PROMS scale among
pediatric cancer patients. Since both clinician-rated and self-
reported evaluations of oral condition in children with cancer
is underreported, the comparison of self-reported PROMS
data with the evaluation of a dental surgeon based on the
WHO OM assessment tool provided significant and novel
pieces of information in the field. Clinician-rated evaluation
of oral conditions in children with cancer has not been
frequently investigated and compared with clinician-rated
data. One of the novelties of the present investigation was the
comparison of self-reported data with the evaluation of a
dental surgeon. Our observations demonstrated the importance
of accurate and clinically meaningful evaluation of OM-
related symptoms of patients in order to prevent and to
properly treat this often neglected side-effect. OM scoring
systems can be divided into two major categories: i)
assessment of symptoms may rely on measurable changes
within the oral cavity determined by a dental expert; and ii)
scoring can be based on patient-reported questionnaires. The
former ones are lesser biased by subjective complaints, the
latter ones represent OHRQoL more reliably. We found
significant associations between PROMS item scores
(representing patients’ subjective assessment of OM) and the
WHO OM score and its components (representing the
objective assessment of OM). Despite of the frequency of OM
in children treated for cancer, this particular side-effect has
rarely been addressed by accurate investigations. Moreover,
there have been no uniformly used scoring systems developed
for the pediatric age group to evaluate the severity of this
complication; therefore, preventive and treatment measures
cannot be based on generally accepted guidelines. According
to a recent study, Gussard et al. [18] suggested that the
association between PROMS and WHO OM scores was
nonlinear and that PROMS represented the OM-related
condition of patients more reliably than the clinician-rated
tools as we pointed it out. Our results demonstrated that
PROMS could be used among pediatric cancer patients older
than 7 years and that it proved to be a reliable indicator of
OM. Since both clinician-rated and self-reported evaluations
of oral condition in children with cancer is underreported, the
comparison of self-reported PROMS data with the evaluation
of a dental surgeon based on the WHO OM assessment tool
provided significant and novel pieces of information in the
field. PROMS is a promising tool to evaluate OM-dependent
OHRQoL in children with cancer. Results obtained with the
use of PROMS questionnaire in this age group may contribute
to the development of clinical guidelines to prevent and treat
antineoplastic therapy-related OM.
Further multicentric studies involving a larger number of
patients and applying a longer observation period may
establish the proper place of the PROMS scale in the
supportive treatment strategy of children with cancer.
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